Company Overview and News

 
Prakash Industries Limited - Updates

2018-08-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
Prakash Industries Limited - Appointment

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
Prakash Industries Limited - Shareholders meeting

2018-07-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
Prakash Industries Limited - Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
Prakash Industries Limited - News Verification

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
Prakash Industries Limited - News Verification

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
Prakash Industries Limited - Statement of deviation(s) or variation(s) under Reg. 32

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

 
IndusInd Bank: Eyes on Q1 provisioning

2018-07-09 thehindubusinessline
Apart from TCS, a leading private sector lender IndusInd Bank, and Prakash Industries will declare their first quarter results for the period ended June, on Tuesday. Though analysts expect IndusInd Bank to report consistent performance, some fear high provisioning for bad loans and MTM on its investment portfolios may drag the bank’s performance. The stock may come under pressure, if the performance fails to meet street expectations.
506022 500470 TTST 532187 TATASTEEL TATLY INDUSINDBK PRAKASH

 
Market Live: Nifty at day#39;s high, Sensex up over 250 pts; Bajaj Auto, Bharti Infratel top gainers

2018-07-04 moneycontrol
Buzzing: Unichem Laboratories share price rallied more than 5 percent intraday after the company received final ANDA approval for its Montelukast Chewable tablets, 4 mg and 5 mg from the United States Food and Drug Administration to market in the US.
BAJAJ-AUTO KOHINOOR BHRYY 500325 UBL RELIANCE 532978 532977 SRTRANSFIN 532478 511218 532783 532121 506690 534816 RIGD SRRQY BJJQY INFRATEL RLNIY 500034 UNICHEMLAB UBHOLDINGS UNBWY 512559 506022 BAJAJFINSV BAJFINANCE PRAKASH DENABANK 507458 DAAWAT

4
Market Live: Sensex up 150 pts despite global weakness; HDFC twins, RIL lead

2018-07-04 moneycontrol
Europe Update: European stocks were slightly lower Wednesday morning, amid elevated tensions between the US and China over looming trade tariffs and investment restrictions.
BAJAJ-AUTO KOHINOOR 500325 533271 UBL RELIANCE ASHOKA 532978 532977 532712 SRTRANSFIN 532478 511218 532783 500470 532121 RCOM RIGD SRRQY BJJQY 500570 TATAMOTORS 509488 RLNIY 500034 GRAPHITE UBHOLDINGS 532967 UNBWY KIRIINDUS BHEL 512559 506022 BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY PRAKASH BRHTY 500103 DENABANK 507458 DAAWAT TTM

 
Prakash Industries stock gains 3% on highest ever quarterly sales volume in Q1

2018-07-04 moneycontrol
Prakash Industries share price gained nearly 3 percent intraday on Wednesday on reporting highest ever quarterly sales volume in Q1FY2019.
506022 PRAKASH

4
Market Live: Rangebound trade continues at Dalal Street; Shriram Transport tumbles

2018-07-04 moneycontrol
Ducon Infratechnologies at upper circuit; Shares of Ducon Infratechnologies were locked at 20 percent upper circuit at Rs 22.80 following new orders for its US subsidiary.
BAJAJ-AUTO 500325 533271 UBL RELIANCE ASHOKA 532978 532977 532712 SRTRANSFIN 532478 511218 500470 532121 RCOM RIGD SRRQY BJJQY 500570 TATAMOTORS 509488 RLNIY 500034 GRAPHITE UBHOLDINGS 532967 UNBWY KIRIINDUS BHEL 506022 BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY PRAKASH BRHTY 500103 DENABANK 507458 TTM

 
Prakash Industries Limited - Press Release

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
506022 PRAKASH

29
Market Live: Sensex falls 300 pts, metals lose shine; Europe falls 1% amid trade tensions

2018-07-02 moneycontrol
Europe Update: Shares in Europe opened sharply lower as investors question the stability of the German government and wider trade links between the European Union and the US.
BAJAJ-AUTO BHRYY 500325 524816 RELIANCE IDBI TCHQY ICLQY 532977 BHRQY 532755 500470 NATCOPHARM 534816 RIGD 500477 INFRATEL 500570 BHARTIARTL TATAMOTORS RLNIY ASHOKLEY 500116 VOD VOD TATAPOWER 532822 AKLD TECHM 532454 506022 TTST VODPF TATASTEEL TATLY PRAKASH IDEA 500102 TPCL 500400 BALLARPUR AKLS TTM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...